OPCABGdiabetesclass III–IV anginahypertension
…). Long-term survival was similar (stratified log-rank p=0.79). OPCABG mitigated the risk of in-hospital mortality in females (1.1% ma…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 181–240 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Clarithromycin17Antibiotic17Anticoagulants17fludarabine17Inclisiran16Atropine16Secukinumab16Caffeine16Salbutamol16Ondansetron16Dapagliflozin16Naloxone16Methylene blue16Anakinra16Fluconazole16Rilpivirine16Analgesics16Rocuronium16Proton pump inhibitor16Osimertinib15Atogepant15ELAFIBRANOR15Pirfenidone15Dabigatran15Obinutuzumab15Rosuvastatin15Medicines15Amphotericin B15Ketorolac15Carbon Monoxide15ACE inhibitors15Phenylephrine15Glucocorticoid15non-steroidal anti-inflammatory drugs15Empagliflozin14Rimegepant14Fremanezumab14FeNO14Olaparib14GA14Relatlimab14IL-1214Lactulose14SpironolacTone14Mannitol14Levothyroxine14bleomycin14Sodium-glucose cotransporter 2 inhibitors14Beta Blockers14Axicabtagene Ciloleucel14adrenaline14Broad-spectrum antibiotics14Etoposide14Tenofovir14Intravenous Immunoglobulin14UPA13LMWH13Liposomal bupivacaine13Baricitinib13Ruxolitinib13
Articles mentioning drugs
10,506 articles · page 349 of 876hydroxychloroquinerituximabJAK inhibitorsmonogenic lupusintensive care interventionslupustertiary pediatric rheumatology centerlupus-likeJAK inhibitorsbiologic therapies+1 more
…C 2021 criteria, while nine met ILE criteria. During follow-up, hydroxychloroquine was used in 14 patients, csDMARDs in 9, JAK inhibitors in 10, a…
MethylprednisoloneimiquimodIMQSLEONFHsystemic lupus erythematosusosteonecrosis of the femoral head (ONFH)Hyperlipidemia
…Objectives Methylprednisolone (mPSL) pulse therapy is an essential treatment for systemic lup…
hydroxychloroquinemethotrexateazathioprineSLEDAI-2Ksystemic lupus erythematosusSLE
…(OR 2.52, 95% CI 1.05–6.46). No associations were observed with hydroxychloroquine use.Abstract PO:02:032 Figure 1Conclusions Autoantibody-defined…
SLEDAI-2Ksystemic lupus erythematosusSLE
…onal biomarkers for monitoring SLE activity being components of SLEDAI-2K, they may be insufficient in distinguishing high disease activi…
99.0%
belimumabCardiovascular diseaseKarolinska University HospitalSLEsystemic lupus erythematosus
…patientsConclusions In this real-world setting of SLE patients, belimumab treatment was associated with decreases in levels of key mediat…
96.5%
hydroxychloroquinelevothyroxineGlucocorticoidsSLEDAI-2KSLEOregentec Diagnostika GmbHradioiodine therapysystemic lupus erhytematosusthyroid surgeryMonobind Inc.+1 more
… (29.4%) patients. Glucocorticoids were received by 41 (80.4%), hydroxychloroquine - 38 (74.5%), immunosuppressants – 18 (35.3%) patients. Over th…
spironolactonemethotrexateprednisolonereninSystemic lupus erythematosusMonash Health Lupus ClinicSLEEndocrine Hypertension Clinicrheumatoid arthritis
… a saline suppression test in 2025 confirmed PA. Treatment with spironolactone (25mg daily, later increased to 37.5mg) is ongoing, with partia…
belimumabmycophenolatecalcineurin inhibitorsLupus podocytopathynephrotic syndromesystemic lupus erythematosusSLEcorticosteroid therapyFSGSMCD
…essants: calcineurin inhibitors (3/5), mycophenolate (2/5), and belimumab (1/5). The most frequent extrarenal manifestations were arthrit…
prednisoneSLEDAI-2Klupus nephritisSLE
…r organ activity, no new disease activity, PGA less than 1, and prednisone less than 7.5mg/day. Organ damage was measured with the SLICC/A…
BelimumabBELHealth Assessment QuestionnaireSLEGSK
…Objectives Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble…
type I IFNIFNSystemic lupus erythematosusSLECD19-CAR T cell therapyCD19-CAR T cell treatment
… I IFN, and revealed that, depending on the culture conditions, type I IFN can decrease galactosylation in B cells.Conclusions Taken toget…